PP2A inhibition with LB100 enhances cisplatin cytotoxicity and overcomes cisplatin resistance in medulloblastoma cells

The protein phosphatase 2A (PP2A) inhibitor, LB100, has been shown in pre-clinical studies to be an effective chemo- and radio-sensitizer for treatment of various cancers. We investigated effects associated with LB100 treatment alone and in combination with cisplatin for medulloblastoma (MB) in vitr...

Descripción completa

Detalles Bibliográficos
Autores principales: Ho, Winson S., Feldman, Michael J., Maric, Dragan, Amable, Lauren, Hall, Matthew D., Feldman, Gerald M., Ray-Chaudhury, Abhik, Lizak, Martin J., Vera, Juan-Carlos, Robison, R. Aaron, Zhuang, Zhengping, Heiss, John D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2016
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4914297/
https://www.ncbi.nlm.nih.gov/pubmed/26799670
http://dx.doi.org/10.18632/oncotarget.6970

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4914297/
https://www.ncbi.nlm.nih.gov/pubmed/26799670
http://dx.doi.org/10.18632/oncotarget.6970

Ejemplares similares